Artiva Biotherapeutics, Inc. filed a current report on November 17, 2026, disclosing that Elizabeth Hougen resigned as a Class III Director effective November 11, 2026.

Key Highlights

  • Resignation date: Elizabeth Hougen notified the company of her resignation on November 11, 2026, effective immediately.
  • Board class: Ms. Hougen served as a Class III Director on the board of directors.
  • No disagreement: According to the filing, her resignation "was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices."
  • Registrant: Artiva Biotherapeutics, Inc. is listed on the Nasdaq Global Market under the symbol NASDAQ:ARTV.
  • Emerging growth company: The filing identifies the registrant as an emerging growth company as defined under applicable SEC rules.

Hougen's Departure from Artiva Biotherapeutics' Board of Directors

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) disclosed in a Form 8-K filed November 17, 2026, that Elizabeth Hougen resigned from the company's board of directors on November 11, 2026. The filing, made under Item 5.02, covers the departure of a director and certain compensatory arrangements of certain officers.

According to the filing, Ms. Hougen submitted her resignation notice to the company on November 11, 2026, with the resignation taking effect immediately. She had held the position of Class III Director on the board. The filing states explicitly that her resignation "was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices."

No replacement director or interim appointment was disclosed in this filing. The report was signed by Fred Aslan, M.D., Chief Executive Officer of Artiva Biotherapeutics, on November 17, 2026. The company is incorporated in Delaware, maintains its principal executive offices at 5505 Morehouse Drive, Suite 100, San Diego, California 92121, and carries Commission File Number 001-42179.

What Was Disclosed

Artiva Biotherapeutics reported the resignation of Class III Director Elizabeth Hougen, effective November 11, 2026, citing no disagreement with company operations, policies, or practices. No successor appointment was announced in the filing.